ESR1 and breast carcinoma: The discovery of recurrent ESR1 mutations within the region of the gene that encodes the ER-LBD in endocrine-resistant ER+ advanced breast cancer introduced new clinical challenges and opportunities for the understanding of the mechanisms of endocrine resistance.